NO315324B1 - Fremgangsmate for fremstilling av fludarabinfosfatlitium-, - natrium-, -kalium-, -kalsium- og -magnesiumsalter, fremgangsmate for rensing avfludarabinfosfat, og fludarabinfosfat som er minst 99,5% rent - Google Patents
Fremgangsmate for fremstilling av fludarabinfosfatlitium-, - natrium-, -kalium-, -kalsium- og -magnesiumsalter, fremgangsmate for rensing avfludarabinfosfat, og fludarabinfosfat som er minst 99,5% rent Download PDFInfo
- Publication number
- NO315324B1 NO315324B1 NO20002962A NO20002962A NO315324B1 NO 315324 B1 NO315324 B1 NO 315324B1 NO 20002962 A NO20002962 A NO 20002962A NO 20002962 A NO20002962 A NO 20002962A NO 315324 B1 NO315324 B1 NO 315324B1
- Authority
- NO
- Norway
- Prior art keywords
- fludarabine phosphate
- solution
- sodium
- potassium
- calcium
- Prior art date
Links
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 title claims description 49
- 229960005304 fludarabine phosphate Drugs 0.000 title claims description 48
- 238000000034 method Methods 0.000 title claims description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims description 12
- 239000011734 sodium Substances 0.000 title claims description 11
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title claims description 10
- 229910052708 sodium Inorganic materials 0.000 title claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims description 9
- 239000011575 calcium Substances 0.000 title claims description 9
- 229910052791 calcium Inorganic materials 0.000 title claims description 9
- 229910052744 lithium Inorganic materials 0.000 title claims description 9
- 159000000003 magnesium salts Chemical class 0.000 title claims description 9
- 239000011591 potassium Substances 0.000 title claims description 9
- 229910052700 potassium Inorganic materials 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 239000003513 alkali Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 22
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 229960000390 fludarabine Drugs 0.000 description 5
- -1 fludarabine phosphates Chemical class 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- REKWWOFUJAJBCL-UHFFFAOYSA-L dilithium;hydrogen phosphate Chemical compound [Li+].[Li+].OP([O-])([O-])=O REKWWOFUJAJBCL-UHFFFAOYSA-L 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical class F* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/19—Purine radicals with arabinosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19756289 | 1997-12-11 | ||
| PCT/EP1998/007651 WO1999029710A2 (fr) | 1997-12-11 | 1998-11-30 | Procede de purification utilise pour preparer du phosphate de fludarabine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20002962D0 NO20002962D0 (no) | 2000-06-09 |
| NO20002962L NO20002962L (no) | 2000-06-09 |
| NO315324B1 true NO315324B1 (no) | 2003-08-18 |
Family
ID=7852365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002962A NO315324B1 (no) | 1997-12-11 | 2000-06-09 | Fremgangsmate for fremstilling av fludarabinfosfatlitium-, - natrium-, -kalium-, -kalsium- og -magnesiumsalter, fremgangsmate for rensing avfludarabinfosfat, og fludarabinfosfat som er minst 99,5% rent |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6046322A (fr) |
| EP (1) | EP1047704B2 (fr) |
| JP (2) | JP4261051B2 (fr) |
| KR (2) | KR100532898B1 (fr) |
| AT (2) | ATE231880T1 (fr) |
| AU (1) | AU739574B2 (fr) |
| CA (1) | CA2313486A1 (fr) |
| CZ (1) | CZ296366B6 (fr) |
| DE (2) | DE59807096D1 (fr) |
| DK (1) | DK1047704T4 (fr) |
| ES (1) | ES2190136T5 (fr) |
| HK (1) | HK1033831A1 (fr) |
| HU (1) | HU226997B1 (fr) |
| IL (1) | IL136283A (fr) |
| NO (1) | NO315324B1 (fr) |
| PL (1) | PL195712B1 (fr) |
| SI (1) | SI1047704T2 (fr) |
| SK (1) | SK283475B6 (fr) |
| TW (1) | TW424093B (fr) |
| WO (1) | WO1999029710A2 (fr) |
| ZA (1) | ZA9811338B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59807096D1 (de) | 1997-12-11 | 2003-03-06 | Schering Ag | Verfahren zur herstellung von fludarabin-phosphat-lithium-, natrium-, kalium-, calcium- und magnesium-salzen, reinigungsverfahren zur herstellung von fludarabin-phosphat und fludarabin-phosphat mit mindestens 99,5 %iger reinheit |
| KR100381930B1 (ko) * | 2000-03-16 | 2003-04-26 | (주)바이오니아 | 유전자 변형 농산물 검출방법 및 검출용 프라이머 |
| WO2003049764A1 (fr) | 2001-12-12 | 2003-06-19 | Fh Faulding & Co Limited | Composition de preservation virale |
| DE10164510A1 (de) * | 2001-12-20 | 2003-07-10 | Schering Ag | Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes |
| CA2487070A1 (fr) * | 2002-05-24 | 2003-12-04 | Sicor Inc. | Composition aqueuse a base de phosphate de fludarabine |
| EP1464708A1 (fr) * | 2003-04-03 | 2004-10-06 | Pro. Bio. Sint. S.p.A. | Procédé de préparation de fludarabine phosphate à partir de 2-fluoroadénine |
| US7698201B2 (en) * | 2006-09-14 | 2010-04-13 | The Prudential Insurance Company Of America | Financial instrument utilizing an optional benefit election |
| CN103040855B (zh) * | 2012-12-28 | 2014-05-14 | 海南锦瑞制药股份有限公司 | 一种磷酸氟达拉滨的药物组合物及其制备方法 |
| EP3342778B1 (fr) * | 2015-08-28 | 2022-01-12 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Forme cristalline de phosphate de fludarabine, procédé de préparation de celle-ci, et application de celle-ci |
| CN109265505A (zh) * | 2018-09-12 | 2019-01-25 | 连云港杰瑞药业有限公司 | 一种磷酸氟达拉滨异构体杂质的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE756704A (fr) | 1969-09-26 | 1971-03-01 | Parke Davis & Co | Procede de production du 5'-phosphate de 9-(beta-d- arabinofuranosyl) adenine et de ses sels |
| US4188378A (en) * | 1978-01-04 | 1980-02-12 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine |
| US4210745A (en) * | 1978-01-04 | 1980-07-01 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine |
| US4357324A (en) * | 1981-02-24 | 1982-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine |
| DE3323621A1 (de) | 1982-07-08 | 1984-03-01 | Yamasa Shoyu K.K., Choshi, Chiba | Pharmazeutisches praeparat mit die antitumor-wirkung verstaerkender wirkung, ein solches praeparat enthaltende chemotherapeutische zusammensetzung und verwendung des praeparates zur unterstuetzung der antitumor-behandlung beim menschen und tier |
| US5110919A (en) * | 1989-12-04 | 1992-05-05 | Ash Stevens, Inc. | Process for the preparation of 2-amino-9-(2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl) adenine and novel intermediates |
| ATE169631T1 (de) * | 1990-06-27 | 1998-08-15 | Ash Stevens Inc | Verfahren zur herstellung von 9-beta-d- arabinofuranosyl-2-fluoroadenin 5'-phosphaten |
| US5602246A (en) | 1992-11-25 | 1997-02-11 | Schering Aktiengesellschaft | Process for the preparation of fludarabine or fludarabine phosphate from guanosine |
| FR2701027B1 (fr) * | 1993-02-01 | 1997-07-18 | Warner Lambert Co | Procede de synthese ameliore du 9-(beta-d-arabinofuranosyl)adenine 5'-phosphate. |
| DE19543052A1 (de) * | 1995-11-06 | 1997-05-07 | Schering Ag | Verfahren zur Herstellung und Reinigung von Fludarabin-Phosphat und die Verwendung von sauren Ionenaustauschern im Verfahren |
| IT1276126B1 (it) | 1995-11-14 | 1997-10-27 | Archimica Spa | Procedimento per la preparazine di 9-((2-idrossietossi)metil) guanina |
| DE59807096D1 (de) | 1997-12-11 | 2003-03-06 | Schering Ag | Verfahren zur herstellung von fludarabin-phosphat-lithium-, natrium-, kalium-, calcium- und magnesium-salzen, reinigungsverfahren zur herstellung von fludarabin-phosphat und fludarabin-phosphat mit mindestens 99,5 %iger reinheit |
| US6174873B1 (en) | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
-
1998
- 1998-11-30 DE DE59807096T patent/DE59807096D1/de not_active Expired - Lifetime
- 1998-11-30 SI SI9830374T patent/SI1047704T2/sl unknown
- 1998-11-30 PL PL98341659A patent/PL195712B1/pl unknown
- 1998-11-30 SK SK887-2000A patent/SK283475B6/sk not_active IP Right Cessation
- 1998-11-30 EP EP98965703A patent/EP1047704B2/fr not_active Expired - Lifetime
- 1998-11-30 CZ CZ20002159A patent/CZ296366B6/cs not_active IP Right Cessation
- 1998-11-30 HU HU0100169A patent/HU226997B1/hu not_active IP Right Cessation
- 1998-11-30 JP JP2000524302A patent/JP4261051B2/ja not_active Expired - Fee Related
- 1998-11-30 AU AU21550/99A patent/AU739574B2/en not_active Ceased
- 1998-11-30 KR KR10-2000-7006262A patent/KR100532898B1/ko not_active IP Right Cessation
- 1998-11-30 AT AT98965703T patent/ATE231880T1/de active
- 1998-11-30 KR KR1020057012396A patent/KR20050085937A/ko not_active Application Discontinuation
- 1998-11-30 ES ES98965703T patent/ES2190136T5/es not_active Expired - Lifetime
- 1998-11-30 IL IL136283A patent/IL136283A/en not_active IP Right Cessation
- 1998-11-30 DK DK98965703T patent/DK1047704T4/da active
- 1998-11-30 DE DE29825173U patent/DE29825173U1/de not_active Expired - Lifetime
- 1998-11-30 WO PCT/EP1998/007651 patent/WO1999029710A2/fr active IP Right Grant
- 1998-11-30 CA CA002313486A patent/CA2313486A1/fr not_active Abandoned
- 1998-12-10 ZA ZA9811338A patent/ZA9811338B/xx unknown
- 1998-12-10 TW TW087120530A patent/TW424093B/zh not_active IP Right Cessation
- 1998-12-10 US US09/208,587 patent/US6046322A/en not_active Expired - Lifetime
-
1999
- 1999-12-23 US US09/471,040 patent/US7547776B1/en not_active Expired - Fee Related
-
2000
- 2000-06-09 NO NO20002962A patent/NO315324B1/no not_active IP Right Cessation
-
2001
- 2001-05-02 HK HK01103119A patent/HK1033831A1/xx not_active IP Right Cessation
-
2005
- 2005-07-14 AT AT0048105U patent/AT8617U1/de not_active IP Right Cessation
-
2008
- 2008-10-27 JP JP2008276079A patent/JP2009040797A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0137455B1 (ko) | 4-아미노-1-하이드록시부틸리덴-1, 1-비스포스폰산 또는 이의 염의 제조방법 | |
| JP2009040797A (ja) | リン酸フルダラビンのリチウム、ナトリウム、カリウム、カルシウム及びマグネシウム塩の製造方法、リン酸フルダラビンを製造するための精製方法及び少なくとも９９．５％の純度を有するリン酸フルダラビン | |
| JP7160946B2 (ja) | （チオ）ニコチンアミドリボフラノシド塩および組成物、製造方法、およびそれらの使用 | |
| JP2921580B2 (ja) | アスコルビン酸−２−ホスフェートの製造法、Ｋ１±０．３Ｍｇ１±０．１５−Ｌ−アスコルベート−２−ホスフェートおよび５，６−イソプロピリデン−アスコルビン酸の製造法 | |
| JPH0643400B2 (ja) | トラセミドの安定な変態の製法 | |
| JP3440129B2 (ja) | グルタミン誘導体の製造法 | |
| CA2000937C (fr) | Preparation de 5'-phosphate de riboflavine (5'-fmn) et de son sel de sodium et de chlorure de l'ester de l'acide riboflavine-4',5'-cyclophosphorique | |
| CA2176181C (fr) | Methode pour l'obtention de d4t de forme polymorphique i | |
| US20060240529A1 (en) | Process for the preparation of fludarabine phosphate from 2-fluoroadenine and fludarabine phosphate salts with amines or ammonia | |
| US5910588A (en) | Crystal modification of 2,4-diamino-6-hydroxymethylpteridine hydrobromide | |
| MXPA00004877A (en) | Method for producing fludarabin phosphate lithium, sodium, potassium, calcium and magnesium salts, purification method for producing fludarabin phosphate and fludarabin phosphate which is at least 99.5%pure | |
| CS9692A3 (en) | Process for preparing 3-fluoropyrimidine nucleosides | |
| US6635753B1 (en) | Process for the preparation of substantially pure stavudine and related intermediates useful in the preparation thereof | |
| CN110511254A (zh) | 一种盐酸克林霉素的结晶方法 | |
| US20080221321A1 (en) | Preparing Salts of Dihydroxychlorotriazine | |
| NZ209285A (en) | Crystalline salts of (r,s)-1-pivaloyloxyethyl (s)-3-(3,4-dihydroxyphenyl)-2-methylalaninate with oxygenated acids, and pharmaceutical compositions | |
| JPH05132470A (ja) | ３−アミノピラジン−２−カルボン酸の製造法および該カルボン酸のアルカリ金属塩の取得方法 | |
| KR20030046269A (ko) | 엘-아스코빌-2-인산에스테르마그네슘의 제조방법 | |
| HU181483B (hu) | Eljárás ( + )-apovinkaminsav-etilészter tisztítására |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |